View full meeting coverage »

Eyetube Meeting Coverage:

2017 Retina World Congress Meeting

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Abicipar Pegol in Phase 2

  Channels: Retina | Posted 1/25/2017

Pravin Dugel, MD, summarizes his presentation on the phase 2 REACH study comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for treatment of wet age-related macular degeneration.

Wet AMD


1 / 12 Series: 2017 Retina World Congress Meeting